Rebollo P, Ortega F, Baltar J M, Alvarez-Ude F, Alvarez Navascués R, Alvarez-Grande J
Nephrology Unit of the Hospital Central de Asturias, Oviedo, Spain.
Nephrol Dial Transplant. 2001 Aug;16(8):1675-80. doi: 10.1093/ndt/16.8.1675.
Previous studies have reported that elderly (aged 65 years or over) end-stage renal disease (ESRD) patients have poorer health-related quality of life (HRQOL) than both younger patients and healthy subjects of the same age. The aim of present study was to evaluate the effect of ESRD and its treatment on the HRQOL, and to determine the effects of age and gender.
A cross-sectional multicentric study was carried out with 485 haemodialysis and renal-transplant patients, using the SF-36 Health Survey to evaluate their HRQOL. SF-36 scores were standardized by age and gender using Spanish normative data. Karnofsky scale score (KS), socio-demographic, and clinical data were also collected.
In renal-replacement therapy (RRT), chronic haemodialysis, and renal-transplant patients, SF-36 standardized scores of elderly patients were higher than in younger patients. Therefore the reduction in HRQOL of elderly patients, in relationship with that of the general population of the same age and gender, was lower than in younger patients. In the case of renal-transplant patients, standardized scores in elderly patients were higher than in the general population for all parameters.
Using standardized scores, elderly patients on renal replacement therapy (haemodialysis and kidney transplant) had relatively better HRQOL than younger patients, and in the case of transplant patients, they had even better HRQOL than in the general population of the same age and gender.
先前的研究报告称，老年（65岁及以上）终末期肾病（ESRD）患者的健康相关生活质量（HRQOL）比年轻患者以及同龄健康受试者更差。本研究的目的是评估ESRD及其治疗对HRQOL的影响，并确定年龄和性别的影响。
对485名血液透析和肾移植患者进行了一项横断面多中心研究，使用SF-36健康调查来评估他们的HRQOL。利用西班牙标准数据按年龄和性别对SF-36评分进行标准化。还收集了卡诺夫斯基量表评分（KS）、社会人口统计学和临床数据。
在肾脏替代治疗（RRT）、慢性血液透析和肾移植患者中，老年患者的SF-36标准化评分高于年轻患者。因此，与同龄和同性别的普通人群相比，老年患者HRQOL的降低幅度低于年轻患者。就肾移植患者而言，老年患者所有参数的标准化评分均高于普通人群。
使用标准化评分，接受肾脏替代治疗（血液透析和肾移植）的老年患者的HRQOL相对比年轻患者更好，而就移植患者而言，他们的HRQOL甚至比同龄和同性别的普通人群更好。
